Company Encyclopedia
View More
name
NextCure
NXTC.US
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors.
1.946 T
NXTC.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    NextCure Files For Offering Of Up To 2.52 Million Shares Of Common Stock By Selling Stockholders - SEC Filing

    Nov 26 (Reuters) - NextCure Inc:* NEXTCURE INC FILES FOR OFFERING OF UP TO 2.52 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: Further company coverage:

    Reuters·
    US
    NXTC
    +5.77%
    Reuters·
    US
    NXTC
    +5.77%

    Piper Sandler Keeps Their Buy Rating on NextCure (NXTC)

    Piper Sandler's Edward Tenthoff reiterated a Buy rating on NextCure (NXTC) with a $15.00 price target. Tenthoff, who covers the Healthcare sector, has an average return of -8.8% and a 33.95% success rate. The analyst consensus on NextCure is a Moderate Buy with an average price target of $19.00.

    Tip Ranks·
    US
    NXTC
    +5.77%
    Tip Ranks·
    US
    NXTC
    +5.77%

    NextCure Inc. to Present at Piper Sandler 37th Annual Healthcare Conference

    NextCure Inc., a clinical-stage biopharmaceutical company, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City on December 3. A live audio webcast will be available on the company's website.

    Reuters·
    US
    NXTC
    +5.77%
    Reuters·
    US
    NXTC
    +5.77%

    NextCure Raises $21.5 Million in PIPE Financing

    NextCure Inc. has closed a $21.5 million private placement, selling 708,428 shares of common stock at $8.52 each and pre-funded warrants for 1,815,049 shares at $8.519 per warrant. The financing, led by Ikarian Capital and others, extends NextCure's cash runway into early 2027 to support its antibody drug conjugate programs. H.C. Wainwright & Co. acted as the exclusive placement agent.

    Reuters·
    US
    NXTC
    +5.77%
    Reuters·
    US
    NXTC
    +5.77%

    Promising Advancements and Strategic Partnerships Drive Buy Rating for NextCure

    Emily Bodnar from H.C. Wainwright maintains a Buy rating for NextCure with a $20 target, citing promising clinical trial advancements, particularly with ADCs SIM0505 and LNCB74. These trials show encouraging results in cancer treatment. Strategic partnerships and FDA trial amendments bolster NextCure's position. Ladenburg Thalmann & Co. also upgraded the stock to Buy with an $18 target. Bodnar, a 3-star analyst, focuses on healthcare stocks like Agenus and Atossa Therapeutics.

    Tip Ranks·
    US
    NXTC
    +5.77%
    Tip Ranks·
    US
    NXTC
    +5.77%
    © 2025 Longbridge｜Disclaimer